Jade Biosciences, Inc. Operating Income
Jade Biosciences, Inc. (JBIO) reported Operating Income of -$58.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Jade Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$58.92M.
- Jade Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$43.45M.
- Jade Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$34.98M.
- Jade Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$27.40M.
- Jade Biosciences, Inc. operating income (loss) for fiscal 2025 was -$113.54M.
- Jade Biosciences, Inc. operating income (loss) for fiscal 2024 was -$74.60M.
- Jade Biosciences, Inc. operating income (loss) for fiscal 2023 was -$81.41M.
- Jade Biosciences, Inc. operating income (loss) for fiscal 2022 was -$53.24M.
| Period end | Operating Income (Loss) 0 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$58.92M 10-Q · filed 2026-08-10 | -$102.36M 10-Q · filed 2026-08-10 | -$137.34M derived: sum of 3 quarters · filed 2026-08-10 | -$164.74M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$43.45M 10-Q · filed 2026-05-07 | -$78.42M derived: sum of 2 quarters · filed 2026-05-07 | -$105.83M derived: sum of 3 quarters · filed 2026-05-07 | -$133.60M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$62.38M derived: sum of 2 quarters · filed 2026-03-06 | -$90.16M derived: sum of 3 quarters · filed 2026-08-10 | -$113.54M 10-K · filed 2026-03-06 | ||
| 2025-09-30 | -$27.40M 10-Q · filed 2025-11-14 | -$55.18M derived: sum of 2 quarters · filed 2026-08-10 | -$78.56M 10-Q · filed 2025-11-14 | -$98.55M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$27.78M 10-Q · filed 2026-08-10 | -$51.16M 10-Q · filed 2026-08-10 | -$71.14M derived: sum of 3 quarters · filed 2026-08-10 | -$86.70M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$23.38M 10-Q · filed 2026-05-07 | -$3.39M 10-Q · filed 2025-04-25 | -$43.37M derived: sum of 2 quarters · filed 2026-05-07 | -$58.92M derived: sum of 3 quarters · filed 2026-05-07 | -$85.09M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$19.98M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$35.54M 10-K · filed 2026-03-06 | -$61.70M derived: sum of 3 quarters · filed 2026-03-06 | -$74.60M 10-K · filed 2025-03-27 | ||
| 2024-09-30 | -$14.96M 10-Q · filed 2025-11-14 | -$17.41M 10-Q · filed 2024-11-12 | -$41.72M derived: sum of 2 quarters · filed 2025-11-14 | -$68.19M 10-Q · filed 2024-11-12 | -$88.40M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$590.00K 10-Q · filed 2025-08-13 | -$26.16M 10-Q · filed 2024-08-12 | -$50.78M 10-Q · filed 2024-08-12 | -$72.85M derived: sum of 3 quarters · filed 2025-04-25 | -$94.22M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | -$24.62M 10-Q · filed 2025-04-25 | -$46.68M derived: sum of 2 quarters · filed 2025-04-25 | -$68.05M derived: sum of 3 quarters · filed 2025-04-25 | -$88.39M derived: sum of 4 quarters · filed 2025-04-25 | ||
| 2023-12-31 | -$22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$43.43M derived: sum of 2 quarters · filed 2025-03-27 | -$63.77M derived: sum of 3 quarters · filed 2025-03-27 | -$81.41M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$21.37M 10-Q · filed 2024-11-12 | -$41.70M derived: sum of 2 quarters · filed 2024-11-12 | -$59.34M 10-Q · filed 2024-11-12 | -$75.19M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$20.34M 10-Q · filed 2024-08-12 | -$37.98M 10-Q · filed 2024-08-12 | -$53.83M derived: sum of 3 quarters · filed 2024-08-12 | -$67.98M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$17.64M 10-Q · filed 2024-05-13 | -$33.49M derived: sum of 2 quarters · filed 2024-05-13 | -$47.64M derived: sum of 3 quarters · filed 2024-05-13 | -$59.86M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$30.00M derived: sum of 2 quarters · filed 2024-03-25 | -$42.22M derived: sum of 3 quarters · filed 2024-03-25 | -$53.24M 10-K · filed 2024-03-25 | ||
| 2022-09-30 | -$14.15M 10-Q · filed 2023-11-13 | -$26.37M derived: sum of 2 quarters · filed 2023-11-13 | -$37.38M 10-Q · filed 2023-11-13 | -$45.65M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | -$12.21M 10-Q · filed 2023-08-14 | -$23.23M 10-Q · filed 2023-08-14 | -$31.50M derived: sum of 3 quarters · filed 2023-08-14 | -$37.70M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$11.02M 10-Q · filed 2023-05-15 | -$19.29M derived: sum of 2 quarters · filed 2023-05-15 | -$25.49M derived: sum of 3 quarters · filed 2023-05-15 | -$31.26M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$14.47M derived: sum of 2 quarters · filed 2023-03-29 | -$20.24M derived: sum of 3 quarters · filed 2023-03-29 | -$23.02M 10-K · filed 2023-03-29 | ||
| 2021-09-30 | -$6.20M 10-Q · filed 2022-11-14 | -$11.97M derived: sum of 2 quarters · filed 2022-11-14 | -$14.75M 10-Q · filed 2022-11-14 | -$18.42M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | -$5.77M 10-Q · filed 2022-08-15 | -$8.55M 10-Q · filed 2022-08-15 | -$12.22M derived: sum of 3 quarters · filed 2022-08-15 | -$14.46M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | -$2.78M 10-Q · filed 2022-05-16 | -$6.44M derived: sum of 2 quarters · filed 2022-05-16 | -$8.69M derived: sum of 3 quarters · filed 2022-05-16 | -$10.31M derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$5.91M derived: sum of 2 quarters · filed 2022-03-30 | -$7.53M derived: sum of 3 quarters · filed 2022-03-30 | -$8.89M 10-K · filed 2022-03-30 | ||
| 2020-09-30 | -$2.24M 10-Q · filed 2021-11-15 | -$3.87M derived: sum of 2 quarters · filed 2021-11-15 | -$5.23M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$1.63M 10-Q · filed 2021-08-16 | -$2.98M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |